Description: Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a drug discovery and development partnerships with Celgene Corporation; Novo Nordisk A/S; Sanofi; Almirall, S.A.; Ferring Pharmaceuticals; Centogene AG; Immuneering Corporation; and LEO Pharma A/S. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Home Page: www.evotec.com
Essener Bogen 7
Hamburg,
22419
Germany
Phone:
49 40 560 81 0
Officers
Name | Title |
---|---|
Ms. Laetitia Rouxel | CFO & Member of Management Board |
Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
Dr. Craig Johnstone Ph.D. | COO & Member of Management Board |
Dr. Christian Wojczewski | Chief Executive Officer |
Ms. Aurelie Dalbiez | Chief People Officer & Member of Management Board |
Mr. Volker Braun | Executive VP and Head of Global Investor Relations & ESG |
Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
Gabriele Hansen | Senior VP & Head of Global Corporate Communications & Marketing |
Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
Dr. David Hallet | Executive Vice President |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 62.8931 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.6299 |
Price-to-Sales TTM: | 2.1343 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 5007 |